1. Home
  2. EPWK vs ENTO Comparison

EPWK vs ENTO Comparison

Compare EPWK & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EPWK
  • ENTO
  • Stock Information
  • Founded
  • EPWK 2011
  • ENTO 2014
  • Country
  • EPWK China
  • ENTO United States
  • Employees
  • EPWK N/A
  • ENTO N/A
  • Industry
  • EPWK
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • EPWK
  • ENTO Health Care
  • Exchange
  • EPWK Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • EPWK 2.3M
  • ENTO 2.3M
  • IPO Year
  • EPWK 2025
  • ENTO 2016
  • Fundamental
  • Price
  • EPWK $0.07
  • ENTO $4.46
  • Analyst Decision
  • EPWK
  • ENTO
  • Analyst Count
  • EPWK 0
  • ENTO 0
  • Target Price
  • EPWK N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • EPWK 84.2M
  • ENTO 193.9K
  • Earning Date
  • EPWK 10-24-2025
  • ENTO 11-14-2025
  • Dividend Yield
  • EPWK N/A
  • ENTO N/A
  • EPS Growth
  • EPWK N/A
  • ENTO N/A
  • EPS
  • EPWK N/A
  • ENTO N/A
  • Revenue
  • EPWK $20,164,008.00
  • ENTO N/A
  • Revenue This Year
  • EPWK N/A
  • ENTO N/A
  • Revenue Next Year
  • EPWK N/A
  • ENTO N/A
  • P/E Ratio
  • EPWK N/A
  • ENTO N/A
  • Revenue Growth
  • EPWK 10.25
  • ENTO N/A
  • 52 Week Low
  • EPWK $0.06
  • ENTO $0.97
  • 52 Week High
  • EPWK $26.00
  • ENTO $5.84
  • Technical
  • Relative Strength Index (RSI)
  • EPWK 28.63
  • ENTO 54.37
  • Support Level
  • EPWK $0.07
  • ENTO $3.89
  • Resistance Level
  • EPWK $0.08
  • ENTO $5.09
  • Average True Range (ATR)
  • EPWK 0.02
  • ENTO 0.65
  • MACD
  • EPWK 0.01
  • ENTO -0.18
  • Stochastic Oscillator
  • EPWK 8.16
  • ENTO 33.01

About EPWK EPWK Holdings Ltd. Class A Ordinary Shares

EPWK Holdings Ltd create an innovative and efficient crowdsourcing platform to connect businesses with great talents. It operates online marketplace to enable businesses (buyers) and service providers (sellers) to find each other. The platform users consist of buyers who seek talents for their jobs and sellers who offer different talents and skills. The company derives revenue mainly comes from providing various value-added services for users on both supply and demand sides.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: